219 related articles for article (PubMed ID: 8541113)
21. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
[TBL] [Abstract][Full Text] [Related]
22. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
23. p53 protein detected by immunohistochemical staining is not always mutant.
MacGeoch C; Barnes DM; Newton JA; Mohammed S; Hodgson SV; Ng M; Bishop DT; Spurr NK
Dis Markers; 1993 Dec; 11(5-6):239-50. PubMed ID: 8082313
[TBL] [Abstract][Full Text] [Related]
24. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
25. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.
Lavarino C; Corletto V; Mezzelani A; Della Torre G; Bartoli C; Riva C; Pierotti MA; Rilke F; Pilotti S
Br J Cancer; 1998; 77(1):125-30. PubMed ID: 9459157
[TBL] [Abstract][Full Text] [Related]
26. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.
Bukholm IK; Nesland JM; Kåresen R; Jacobsen U; Børresen AL
J Pathol; 1997 Feb; 181(2):140-5. PubMed ID: 9120716
[TBL] [Abstract][Full Text] [Related]
27. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.
Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H
J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827
[TBL] [Abstract][Full Text] [Related]
28. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
30. The status of p53 in the metastatic progression of colorectal cancer.
Heide I; Thiede C; Sonntag T; de Kant E; Neubauer A; Jonas S; Peter FJ; Neuhaus P; Herrmann R; Huhn D; Rochlitz CF
Eur J Cancer; 1997 Jul; 33(8):1314-22. PubMed ID: 9301461
[TBL] [Abstract][Full Text] [Related]
31. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
32. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
33. p53 expression and prognosis in gastric carcinoma.
Martin HM; Filipe MI; Morris RW; Lane DP; Silvestre F
Int J Cancer; 1992 Apr; 50(6):859-62. PubMed ID: 1555884
[TBL] [Abstract][Full Text] [Related]
34. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of serum p53 antibodies in lung cancer.
Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
[TBL] [Abstract][Full Text] [Related]
36. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.
Børresen AL; Hovig E; Smith-Sørensen B; Malkin D; Lystad S; Andersen TI; Nesland JM; Isselbacher KJ; Friend SH
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8405-9. PubMed ID: 1924299
[TBL] [Abstract][Full Text] [Related]
37. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.
Casson AG; Tammemagi M; Eskandarian S; Redston M; McLaughlin J; Ozcelik H
Mol Pathol; 1998 Apr; 51(2):71-9. PubMed ID: 9713589
[TBL] [Abstract][Full Text] [Related]
38. Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status.
Domínguez G; Silva J; Silva JM; García JM; Larrondo FJ; Vargas J; Sanfrutos L; Provencio M; España P; Bonilla F
Genes Chromosomes Cancer; 2001 Jun; 31(2):99-106. PubMed ID: 11319797
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
